HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

Roivant’s CEO thinks China is a ‘red herring’

China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring. 

By FierceBiotech · Apr 18, 2026 · via FierceBiotech
Roivant’s CEO thinks China is a ‘red herring’

Image: FierceBiotech

Tags
policyformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
PolicyFierceBiotech ↗
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump adm…
Apr 18, 2026
Trump Administration Again Blocks UNFPA Funding Under Kemp-Kasten
PolicyBriefing
Trump Administration Again Blocks UNFPA Funding Under Kemp-Kasten
Using the Kemp-Kasten amendment, the administration withheld $32.5 million in FY2025 UNFPA support and is expe…
Apr 17, 2026
Predictive analytics pushes lab data into drug commercialization policy
PolicyBriefing
Predictive analytics pushes lab data into drug commercialization policy
Quest Diagnostics highlights growing pharma use of predictive analytics and lab results to improve launch targ…
Apr 17, 2026